Susceptibility to seizure-induced sudden death in DBA/2 mice is altered by adenosine.
Sudden unexpected death in epilepsy (SUDEP) is rare but is an important public health burden due to the number of patient years lost. Respiratory dysfunction following generalized convulsive seizure is a common sequence of events in witnessed SUDEP cases. The DBA/2 mouse model of SUDEP exhibits generalized convulsive audiogenic seizures (AGSz), which result in seizure-induced respiratory arrest (S-IRA) in ∼75% of these animals, while the remaining DBA/2 mice exhibit AGSz without S-IRA. SUDEP induction may involve actions of adenosine, which is released during generalized seizures in animals and patients and is known to depress respiration. This study examined the effects of systemic administration of agents that alter the actions of adenosine on the incidence of S-IRA in DBA/2 mice. DBA/2 mice that consistently exhibited AGSz without S-IRA showed a significantly increased incidence of S-IRA following treatment with 5-iodotubercidin, which blocks adenosine metabolism. Treatment of DBA/2 mice that consistently exhibited AGSz followed by S-IRA with a non-selective adenosine antagonist, caffeine, or an A2A adenosine receptor subtype-selective antagonist (SCH 442416) significantly reduced S-IRA incidence. By contrast, an A1 adenosine receptor antagonist (DPCPX) was not effective in reducing S-IRA incidence. These findings suggest that preventative approaches for SUDEP should consider agents that reduce the actions of adenosine.
Departments of Pharmacology and Neurology, Southern Illinois University School of Medicine, P.O. Box 19629, Springfield, IL 62794-9629, United States. Electronic address: cfaingold@siumed.edu.
Carl L
CL
Faingold
Departments of Pharmacology and Neurology, Southern Illinois University School of Medicine, P.O. Box 19629, Springfield, IL 62794-9629, United States.
Marc
M
Randall
Departments of Pharmacology and Neurology, Southern Illinois University School of Medicine, P.O. Box 19629, Springfield, IL 62794-9629, United States.
Srinivasa P
SP
Kommajosyula
D000241:Adenosine / Q000378:metabolism*; D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D003645:Death, Sudden / Q000209:etiology* / Q000517:prevention & control; D004195:Disease Models, Animal; D004198:Disease Susceptibility / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D008811:Mice, Inbred DBA; D058915:Purinergic P1 Receptor Antagonists / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D018047:Receptors, Purinergic P1 / Q000378:metabolism*; D012119:Respiration / Q000187:drug effects; D012120:Respiration Disorders / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D012640:Seizures / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism*; D014372:Tubercidin / Q000031:analogs & derivatives; D014970:Xanthines / Q000494:pharmacology
D058915:Purinergic P1 Receptor Antagonists; D011720:Pyrazoles; D011743:Pyrimidines; D018047:Receptors, Purinergic P1; D014970:Xanthines; C034214:5-iodotubercidin; D002110:Caffeine; C051360:1,3-dipropyl-8-cyclopentylxanthine; D000241:Adenosine; D014372:Tubercidin; C416650:SCH 442416
Adenosine; Caffeine; DBA/2 mice; Respiratory arrest; SUDEP